Neurocrine Biosciences shares rose 6.46% over the past week, significantly outperforming the Zacks Medical - Drugs industry's 0.55% gain. The stock also posted an 8.84% monthly increase versus the industry's 0.36%, and has climbed 28.75% over the past quarter and 31.67% over the past year, far exceeding the S&P 500's 14.95% and 21.93% respective returns. The company currently holds a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of A. Over the past two months, seven full-year earnings estimates were revised upward with none lower, lifting the consensus estimate from $8.04 to $9.47; for the next fiscal year, six estimates moved higher with no downward revisions.
Neurocrine Biosciences IncStrong price performance, upward earnings estimate revisions, and a Zacks Rank #1 (Strong Buy) indicate positive financial/valuation sentiment.